Observational studyActa paediatrica (Oslo, Norway : 1992)2026
Doxapram Exposure Was Not Associated With Adverse Neurodevelopmental Outcomes in Very Low Birth Weight Infants: A Monocentric Retrospective Cohort Study.
Observational study in Acta paediatrica (Oslo, Norway : 1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimDoxapram is used as an additional therapy for apnea of prematurity when standard treatments such as caffeine or continuous positive airway pressure are insufficient, but its impact on long-term neurodevelopment remains uncertain. This study evaluated the association between Doxapram exposure and neurodevelopmental outcomes in very low birth weight infants (VLBWI), with a focus on potential dose-dependent effects.
methodsIn this monocentric retrospective cohort study, VLBWI with gestational age ≤ 32 weeks were included. Infants treated with Doxapram (n = 140) were compared to untreated controls (n = 280) matched by year of birth. Exposure was stratified by cumulative dose. The primary outcome was neurodevelopment at 24 months corrected age assessed by the mental development index or global development quotient (MDI/GDQ). Secondary outcomes included mortality, growth parameters and neurological outcomes. Multivariable logistic regression adjusted for confounders.
resultsNeurodevelopment did not differ between groups (MDI/GDQ: 94.2 ± 21.2 vs. 97.7 ± 14.8; p = 0.1), nor did mortality (5.0% vs. 6.8%; p = 0.53). No dose-dependent associations were observed. Secondary outcomes were comparable.
conclusionsDoxapram exposure was not associated with adverse neurodevelopmental outcomes in VLBWI within the investigated dosage range, although definitive conclusions on drug safety cannot be drawn from medium-sized cohorts and confirmation in prospective randomised studies is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.